← All trials
NCT06042049
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2023
- Primary completion
- Sep 18, 2024
- Completion date
- Apr 14, 2025
- First posted
- Sep 18, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 33
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.